BACKGROUND: Trimethoprim-sulfamethoxazole (SXT) reduces morbidity and mortality among HIV-infected persons in Africa, but its impact on antimicrobial resistance is of concern. METHODS: HIV-uninfected (group A), HIV-infected but not requiring SXT (group B), and HIV-infected and eligible for SXT (group C) adults were recruited into a prospective observational cohort study in Moshi, Tanzania. Stool was examined for Escherichia coli nonsusceptible to SXT at baseline and at weeks 1, 2, 4, and 24. General estimating equation models were used to assess differences in susceptibility over time and cross-resistance to other antimicrobials. RESULTS: Of 181 subjects, 118 (65.1%) were female and the median (range) age was 36 (20 to 72) years. At baseline, E. coli nonsusceptible to SXT was isolated from 23 (53.5%) of 43 patients in group A, 25 (67.6%) of 37 patients in group B, and 37 (64.9%) of 57 patients in group C. The odds ratios (P value) for SXT nonsusceptibility in group C at weeks 1, 2, 4, and 24 compared with baseline were 3.4 (0.013), 3.0 (0.019), 2.9 (0.030), and 1.5 (0.515), respectively. SXT nonsusceptibility was associated with nonsusceptibility to ampicillin, chloramphenicol, ciprofloxacin, and nalidixic acid (P <or= 0.006). CONCLUSION: In Tanzania, carriage of fecal E. coli nonsusceptible to SXT is common before SXT prophylaxis. Initiation of SXT leads to further loss of susceptibility to SXT and to other antimicrobials.
BACKGROUND:Trimethoprim-sulfamethoxazole (SXT) reduces morbidity and mortality among HIV-infectedpersons in Africa, but its impact on antimicrobial resistance is of concern. METHODS:HIV-uninfected (group A), HIV-infected but not requiring SXT (group B), and HIV-infected and eligible for SXT (group C) adults were recruited into a prospective observational cohort study in Moshi, Tanzania. Stool was examined for Escherichia coli nonsusceptible to SXT at baseline and at weeks 1, 2, 4, and 24. General estimating equation models were used to assess differences in susceptibility over time and cross-resistance to other antimicrobials. RESULTS: Of 181 subjects, 118 (65.1%) were female and the median (range) age was 36 (20 to 72) years. At baseline, E. coli nonsusceptible to SXT was isolated from 23 (53.5%) of 43 patients in group A, 25 (67.6%) of 37 patients in group B, and 37 (64.9%) of 57 patients in group C. The odds ratios (P value) for SXT nonsusceptibility in group C at weeks 1, 2, 4, and 24 compared with baseline were 3.4 (0.013), 3.0 (0.019), 2.9 (0.030), and 1.5 (0.515), respectively. SXT nonsusceptibility was associated with nonsusceptibility to ampicillin, chloramphenicol, ciprofloxacin, and nalidixic acid (P <or= 0.006). CONCLUSION: In Tanzania, carriage of fecal E. coli nonsusceptible to SXT is common before SXT prophylaxis. Initiation of SXT leads to further loss of susceptibility to SXT and to other antimicrobials.
Authors: Rony Zachariah; Marie-Paule L Spielmann; Christina Chinji; Patrick Gomani; Victor Arendt; Nicola J Hargreaves; Felix M Salaniponi; Anthony D Harries Journal: AIDS Date: 2003-05-02 Impact factor: 4.177
Authors: R W Frenck; I Nakhla; Y Sultan; S B Bassily; Y F Girgis; J David; T C Butler; N I Girgis; M Morsy Journal: Clin Infect Dis Date: 2000-11-06 Impact factor: 9.079
Authors: Susan C Morpeth; John A Crump; Humphrey J Shao; Habib O Ramadhani; Peter R Kisenge; Cindy A Moylan; Susanna Naggie; L Brett Caram; Keren Z Landman; Noel E Sam; Dafrosa K Itemba; John F Shao; John A Bartlett; Nathan M Thielman Journal: AIDS Res Hum Retroviruses Date: 2007-10 Impact factor: 2.205
Authors: R Zachariah; A D Harries; M P Spielmann; V Arendt; D Nchingula; R Mwenda; O Courtielle; P Kirpach; B Mwale; F M L Salaniponi Journal: Trans R Soc Trop Med Hyg Date: 2002 Mar-Apr Impact factor: 2.184
Authors: Frank B D Mwaungulu; Sian Floyd; Amelia C Crampin; Simplex Kasimba; Simon Malema; Huxley Kanyongoloka; Anthony D Harries; Judith R Glynn; Paul E M Fine Journal: Bull World Health Organ Date: 2004-05 Impact factor: 9.408
Authors: Amy S Labar; Jennifer S Millman; Ellen Ruebush; Japheth A Opintan; Rima A Bishar; A Oladipo Aboderin; Mercy J Newman; Adebayo Lamikanra; Iruka N Okeke Journal: PLoS One Date: 2012-05-30 Impact factor: 3.240
Authors: Freeman Chabala; Mutinta Madubasi; Mable Mwale Mutengo; Njeleka Banda; Kaunda Yamba; Patrick Kaonga Journal: Int J Environ Res Public Health Date: 2020-05-12 Impact factor: 3.390
Authors: Jessica C Seidman; Lashaunda B Johnson; Joshua Levens; Harran Mkocha; Beatriz Muñoz; Ellen K Silbergeld; Sheila K West; Christian L Coles Journal: Front Microbiol Date: 2016-09-07 Impact factor: 5.640